Search

Your search keyword '"Kaiser, Ulrich"' showing total 183 results

Search Constraints

Start Over You searched for: Author "Kaiser, Ulrich" Remove constraint Author: "Kaiser, Ulrich" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
183 results on '"Kaiser, Ulrich"'

Search Results

8. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

9. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

10. Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

11. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

12. The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany

13. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

14. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

15. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

16. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

17. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

18. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma

21. " I can't do it anymore": a qualitative study on the emergence of crisis in outpatient palliative care—the perspective of family caregivers.

22. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

23. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

24. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

28. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

29. Initial experiences with dynamic, quality indicator-based multimodal tissue analysis (M-Ref) with parallel assessment of viscosity and shear wave elastography in liver parenchyma alterations1.

30. Handheld ultrasound for portal vein evaluation in pediatric patients.

31. Use of a handheld system for interventional ultrasound with puncture and biopsy in an in vitro liver model.

34. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

36. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

39. Winning entry of the creative competition.

41. Wireless handheld ultrasound for internal jugular vein assessment in pediatric patients.

44. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

45. Novel high-resolution contrast agent ultrasound techniques HiFR CEUS and SR CEUS in combination with shear wave elastography, fat assessment and viscosity of liver parenchymal changes and tumors.

46. Comparison of wireless handheld ultrasound and high-end ultrasound in pediatric patients with venous malformations – First results.

47. Initial description of the novel handheld wireless ultrasound device TE Air with Doppler and Color Duplex imaging.

48. Color Mapping using Ultrasound System-integrated Perfusion Software for Evaluation of Focal Liver Lesions: A Possible First Step for More Independent Reading.

49. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Catalog

Books, media, physical & digital resources